IRIS Accounts Production v25.1.4.42 08751823 Board of Directors 31.12.24 1.1.24 31.12.24 31.12.24 Medium entities These accounts have been prepared in accordance with the provisions applicable to companies subject to the medium-sized companies regime. true true false true true false false false true false Ordinary 0 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh087518232023-12-31087518232024-12-31087518232024-01-012024-12-31087518232022-12-31087518232023-01-012023-12-31087518232023-12-3108751823ns15:EnglandWales2024-01-012024-12-3108751823ns14:PoundSterling2024-01-012024-12-3108751823ns10:Director12024-01-012024-12-3108751823ns10:Consolidated2024-12-3108751823ns10:ConsolidatedGroupCompanyAccounts2024-01-012024-12-3108751823ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3108751823ns10:Consolidatedns10:MediumEntities2024-01-012024-12-3108751823ns10:Consolidatedns10:Audited2024-01-012024-12-3108751823ns10:SmallCompaniesRegimeForAccounts2024-01-012024-12-3108751823ns10:Consolidated2024-01-012024-12-3108751823ns10:Consolidatedns10:Medium-sizedCompaniesRegimeForDirectorsReport2024-01-012024-12-3108751823ns10:Consolidatedns10:Medium-sizedCompaniesRegimeForAccounts2024-01-012024-12-3108751823ns10:FullAccounts2024-01-012024-12-310875182312024-01-012024-12-3108751823ns10:OrdinaryShareClass12024-01-012024-12-3108751823ns10:Director22024-01-012024-12-3108751823ns10:RegisteredOffice2024-01-012024-12-3108751823ns10:Consolidated2023-01-012023-12-3108751823ns5:CurrentFinancialInstruments2024-12-3108751823ns5:CurrentFinancialInstruments2023-12-3108751823ns5:ShareCapital2024-12-3108751823ns5:ShareCapital2023-12-3108751823ns5:SharePremium2024-12-3108751823ns5:SharePremium2023-12-3108751823ns5:RetainedEarningsAccumulatedLosses2024-12-3108751823ns5:RetainedEarningsAccumulatedLosses2023-12-3108751823ns5:ShareCapital2022-12-3108751823ns5:RetainedEarningsAccumulatedLosses2022-12-3108751823ns5:SharePremium2022-12-3108751823ns5:RetainedEarningsAccumulatedLosses2024-01-012024-12-3108751823ns5:NetGoodwill2024-01-012024-12-3108751823ns5:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3108751823ns5:LongLeaseholdAssetsns5:LandBuildings2024-01-012024-12-3108751823ns5:PlantMachinery2024-01-012024-12-3108751823ns5:FurnitureFittings2024-01-012024-12-3108751823ns5:CostValuation2023-12-3108751823ns10:OrdinaryShareClass12024-12-31
REGISTERED NUMBER: 08751823 (England and Wales)















Group Strategic Report, Report of the Directors and

Audited Consolidated Financial Statements for the Year Ended 31 December 2024

for

Lindisfarne Healthcare(Holdings) Limited

Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)






Contents of the Consolidated Financial Statements
for the Year Ended 31 December 2024




Page

Company Information 1

Group Strategic Report 2

Report of the Directors 4

Report of the Independent Auditors 6

Consolidated Income Statement 10

Consolidated Other Comprehensive Income 11

Consolidated Balance Sheet 12

Company Balance Sheet 13

Consolidated Statement of Changes in Equity 14

Company Statement of Changes in Equity 15

Consolidated Cash Flow Statement 16

Notes to the Consolidated Cash Flow Statement 17

Notes to the Consolidated Financial Statements 18


Lindisfarne Healthcare(Holdings) Limited

Company Information
for the Year Ended 31 December 2024







DIRECTORS: A Cornford
V Keenan



REGISTERED OFFICE: Willowbrook House
St Arvans Crescent
St Mellons
Cardiff
CF3 0FD



REGISTERED NUMBER: 08751823 (England and Wales)



SENIOR STATUTORY AUDITOR: Stephen Horrigan FCA



AUDITORS: DHB Accountants Limited
Chartered Accountants
Statutory Auditors
110 Whitchurch Road
Cardiff
CF14 3LY

Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Group Strategic Report
for the Year Ended 31 December 2024

The directors present their strategic report of the company and the group for the year ended 31 December 2024.

REVIEW OF BUSINESS
The results for the financial year are set out in the attached profit & loss account and the balance sheet sets out the financial position of the company as at 31 December 2024.

During the year ended 31 December 2024 interest rates remained higher than in previous years which has had a continued effect upon the profitability of the company as a result of the increase in borrowing costs.When coupled with the increases in minimum wage these factors have presented some challenges to cash flow.

Having regard to the comments made above the directors consider the results for the year to be satisfactory and they are confident that underlying profitability will improve in the forthcoming financial year as the company continues to maintain and consolidate it's position in a competitive market.

Turnover increased during the year and gross margin achieved remained consistent. One of the key indicators used by the company is wage costs relative to turnover. This information is confidential as it is commercially sensitive but the percentage of wages excluding directors salaries to turnover has increased as compared to previous years as a result in increases in minimum wage and associated costs.

As disclosed elsewhere in the accounts fixed assets are stated at cost. In November 2024 a valuation was carried out which confirmed that the open market value of the business is significantly in excess of the amount at which the assets are stated in the accounts. A revaluation was carried out that restated the long leasehold interest at fair value in the accounts.

PRINCIPAL RISKS AND UNCERTAINTIES
The director undertakes periodic reviews of the operating risks facing the group.

The company and it's subsidiary are exposed to certain financial risks and the directors have developed and evaluated strategies and programmes on internal controls to address the principal risks identified. Those identified are controlled as follows :

Credit Risk : The company's principal assets comprise investment in a subsidiary company and amounts due from that company. Provisions are made if required for irrecoverable amounts and impairment provision made where a loss event is identifiable and which could give rise to a reduction in the recoverability of cash flows.

Liquidity Risk : In order to maintain liquidity to ensure that there are sufficient funds available for ongoing operations and future developments the company uses a mixture of long and short term debt finance.

Cash Flow Risk : The trading activities of the company and it's subsidiary are all within the United Kingdom and therefore it is not expected to be exposed to exchange rate fluctuations and is also not concerned as to any impact the effects that Brexit might have.

Interest rate risk: The subsidiary company has bank borrowings that are linked to bank base rate and costs have increased as a result of rise in the rates. The directors implemented a strategy of efficiencies designed to result in savings to meet these additional costs and have a strategy in place if this becomes unmanageable.

Regular management accounts are prepared and reviewed by the director and trends and variances considered and investigated as to any impact upon the business and it's cash flow.Because of the straightforward nature of the trading operations in the directors analysis using Key Performance Indicators ( KPI'S ) is not necessary for an understanding of the development, performance or position of the business.

Exposure to adverse movements in interest rates is not considered by the directors to be a significant risk as it is manageable within existing trading operations .


Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Group Strategic Report
for the Year Ended 31 December 2024

FINANCIAL KEY PERFORMANCE INDICATORS
One of the groups key indicators is wage costs expressed as a percentage of turnover. This information is confidential and regarded as commercially sensitive. However, the directors are of the view that the percentages achieved by the group are at an acceptable level particularly when increased costs as a result of the introduction of Auto Enrolment are taken into account.

Given the straightforward nature of the business of the group the directors are of the opinion that analysis of performance using key performance indicators is not necessary for an understanding of the development, performance or position of the business of the group.

ON BEHALF OF THE BOARD:





A Cornford - Director


19 September 2025

Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Report of the Directors
for the Year Ended 31 December 2024

The directors present their report with the financial statements of the company and the group for the year ended 31 December 2024.

PRINCIPAL ACTIVITY
The principal activity of the group in the year under review was that of the operation of a high quality Nursing and Care Home providing general nursing care but specialising particularly in the care of the elderly and mentally infirmed care users. (EMI)

DIVIDENDS
During the year a dividend was made available to the estate of the late Mrs A F Kelly of £900,000 to be applied against a debt due by the estate to a subsidiary company.

DIRECTORS
The directors shown below have held office during the whole of the period from 1 January 2024 to the date of this report.

A Cornford
V Keenan

STATEMENT OF DIRECTORS' RESPONSIBILITIES
The directors are responsible for preparing the Group Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the group and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's and the group's transactions and disclose with reasonable accuracy at any time the financial position of the company and the group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.


STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the group's auditors are unaware, and each director has taken all the steps that she ought to have taken as a director in order to make herself aware of any relevant audit information and to establish that the group's auditors are aware of that information.

Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Report of the Directors
for the Year Ended 31 December 2024


AUDITORS
Under section 487(2) of the Companies Act 2006, DHB Accountants Limited will be deemed to have been reappointed as auditors 28 days after these financial statements were sent to members or 28 days after the latest date prescribed for filing the financial statements with the registrar whichever is the earlier.

ON BEHALF OF THE BOARD:



A Cornford - Director


19 September 2025

Report of the Independent Auditors to the Members of
Lindisfarne Healthcare(Holdings) Limited

Opinion
We have audited the financial statements of Lindisfarne Healthcare(Holdings) Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 December 2024 which comprise the Consolidated Income Statement, Consolidated Other Comprehensive Income, Consolidated Balance Sheet, Company Balance Sheet, Consolidated Statement of Changes in Equity, Company Statement of Changes in Equity, Consolidated Cash Flow Statement and Notes to the Consolidated Cash Flow Statement, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
-give a true and fair view of the state of the group's and of the parent company affairs as at 31 December 2024 and of the group's profit for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and the parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information
The directors are responsible for the other information. The other information comprises the information in the Group Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Group Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Group Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Report of the Independent Auditors to the Members of
Lindisfarne Healthcare(Holdings) Limited


Matters on which we are required to report by exception
In the light of the knowledge and understanding of the group and the parent company and its environment obtained in the course of the audit, we have not identified material misstatements in the Group Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities set out on page four, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the group's and the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or the parent company or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Members of
Lindisfarne Healthcare(Holdings) Limited


Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

As part of planning our audit, we determined materiality and assessed the risks of material misstatement in the financial statement's, including how fraud may occur by enquiring of management of its own consideration of fraud. In particular we looked at where management made subjective judgements, for example in respect of significant accounting estimates that involved making assumptions and considering future events that are inherently uncertain. We also considered potential financial or other pressures , opportunity and motivations for fraud. As part of this discussion we identified the internal controls to mitigate risks related to fraud or non-compliance with laws and regulations and how management monitor these processes. Appropriate procedures included the review and testing of manual journals and key estimates and judgements made by management.

We gained an understanding of the legal and regulatory frameworks that are applicable to the company and the industry in which it operates, drawing on our wide experience, and considered whether there had been any acts by the company that may have been contrary to these laws and regulations, including fraud. We focused on laws and regulations that could give rise to material misstatement in the financial statements, including, but not limited to, the Companies Act 2006, UK tax legislation and relevant local laws and regulations. We made enquiries of management with regards to compliance with the above laws and regulations and corroborated where necessary to other necessary evidence.

Our audit tests included agreeing the financial statements disclosures to underlying supporting documentation and enquiries with management.

We did not identify any key audit matters relating to irregularities, including fraud. As in all of our audits, we also addressed the risk of management override on internal controls including testing journals and evaluation of whether there was any evidence of bias by management that represented a risk of material misstatement due to fraud.

Our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognizing that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment, for example, forgery, misrepresentation or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from events and transactions reflected in the financial statement's, the less likely we are to become aware of it.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Report of the Independent Auditors to the Members of
Lindisfarne Healthcare(Holdings) Limited


Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




Stephen Horrigan FCA (Senior Statutory Auditor)
for and on behalf of DHB Accountants Limited
Chartered Accountants
Statutory Auditors
110 Whitchurch Road
Cardiff
CF14 3LY

19 September 2025

Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Consolidated
Income Statement
for the Year Ended 31 December 2024

2024 2023
Notes £    £   

TURNOVER 6,348,390 5,970,525

Cost of sales 596,701 559,611
GROSS PROFIT 5,751,689 5,410,914

Administrative expenses 4,908,452 4,849,596
OPERATING PROFIT 4 843,237 561,318

Gain/loss on revaluation of tangible
assets

2,868,073

-
3,711,310 561,318

Interest payable and similar expenses 5 366,092 343,781
PROFIT BEFORE TAXATION 3,345,218 217,537

Tax on profit 6 850,500 138,590
PROFIT FOR THE FINANCIAL YEAR 2,494,718 78,947
Profit attributable to:
Owners of the parent 2,494,718 78,947

Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Consolidated
Other Comprehensive Income
for the Year Ended 31 December 2024

2024 2023
Notes £    £   

PROFIT FOR THE YEAR 2,494,718 78,947


OTHER COMPREHENSIVE INCOME - -
TOTAL COMPREHENSIVE INCOME
FOR THE YEAR

2,494,718

78,947

Total comprehensive income attributable to:
Owners of the parent 2,494,718 78,947

Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Consolidated Balance Sheet
31 December 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 9 - -
Tangible assets 10 8,100,000 5,261,031
Investments 11 3,667,923 3,667,923
11,767,923 8,928,954

CURRENT ASSETS
Stocks 12 35,000 35,000
Debtors 13 1,178,632 2,307,262
Cash at bank and in hand 87,934 20,986
1,301,566 2,363,248
CREDITORS
Amounts falling due within one year 14 1,059,631 1,173,817
NET CURRENT ASSETS 241,935 1,189,431
TOTAL ASSETS LESS CURRENT
LIABILITIES

12,009,858

10,118,385

CREDITORS
Amounts falling due after more than one
year

15

(4,109,564

)

(4,536,847

)

PROVISIONS FOR LIABILITIES 18 (1,127,695 ) (403,657 )
NET ASSETS 6,772,599 5,177,881

CAPITAL AND RESERVES
Called up share capital 19 2 2
Share premium 20 1,549,998 1,549,998
Fair value reserve 20 2,151,055 -
Retained earnings 20 3,071,544 3,627,881
SHAREHOLDERS' FUNDS 6,772,599 5,177,881

The financial statements were approved by the Board of Directors and authorised for issue on 19 September 2025 and were signed on its behalf by:





A Cornford - Director


Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Company Balance Sheet
31 December 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 9 - -
Tangible assets 10 - -
Investments 11 3,124,539 3,124,539
3,124,539 3,124,539

CREDITORS
Amounts falling due within one year 14 124,539 124,539
NET CURRENT LIABILITIES (124,539 ) (124,539 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

3,000,000

3,000,000

CAPITAL AND RESERVES
Called up share capital 19 2 2
Share premium 1,549,998 1,549,998
Retained earnings 1,450,000 1,450,000
SHAREHOLDERS' FUNDS 3,000,000 3,000,000

Company's profit for the financial year 900,000 -

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Directors and authorised for issue on 19 September 2025 and were signed on its behalf by:





A Cornford - Director


Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Consolidated Statement of Changes in Equity
for the Year Ended 31 December 2024

Called up Fair
share Retained Share value Total
capital earnings premium reserve equity
£    £    £    £    £   
Balance at 1 January 2023 2 3,548,934 1,549,998 - 5,098,934

Changes in equity
Total comprehensive income - 78,947 - - 78,947
Balance at 31 December 2023 2 3,627,881 1,549,998 - 5,177,881

Changes in equity
Dividends - (900,000 ) - - (900,000 )
Total comprehensive income - 343,663 - 2,151,055 2,494,718
Balance at 31 December 2024 2 3,071,544 1,549,998 2,151,055 6,772,599

Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Company Statement of Changes in Equity
for the Year Ended 31 December 2024

Called up
share Retained Share Total
capital earnings premium equity
£    £    £    £   
Balance at 1 January 2023 2 1,450,000 1,549,998 3,000,000

Changes in equity
Balance at 31 December 2023 2 1,450,000 1,549,998 3,000,000

Changes in equity
Dividends - (900,000 ) - (900,000 )
Total comprehensive income - 900,000 - 900,000
Balance at 31 December 2024 2 1,450,000 1,549,998 3,000,000

Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Consolidated Cash Flow Statement
for the Year Ended 31 December 2024

2024 2023
Notes £    £   
Cash flows from operating activities
Cash generated from operations 1 1,916,324 647,806
Interest paid (366,092 ) (343,781 )
Tax paid (92,127 ) (99,884 )
Net cash from operating activities 1,458,105 204,141

Cash flows from investing activities
Purchase of tangible fixed assets (67,376 ) (11,000 )
Net cash from investing activities (67,376 ) (11,000 )

Cash flows from financing activities
New loans in year - 250,000
Loan repayments in period (427,283 ) (360,322 )
Equity dividends paid (900,000 ) -
Net cash from financing activities (1,327,283 ) (110,322 )

Increase in cash and cash equivalents 63,446 82,819
Cash and cash equivalents at
beginning of year

2

(46,594

)

(129,413

)

Cash and cash equivalents at end of
year

2

16,852

(46,594

)

Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Notes to the Consolidated Cash Flow Statement
for the Year Ended 31 December 2024

1. RECONCILIATION OF PROFIT BEFORE TAXATION TO CASH GENERATED FROM
OPERATIONS

2024 2023
£    £   
Profit before taxation 3,345,218 217,537
Depreciation charges 96,480 129,480
Gain on revaluation of fixed assets (2,868,073 ) -
Finance costs 366,092 343,781
939,717 690,798
Decrease/(increase) in trade and other debtors 1,128,630 (20,743 )
Decrease in trade and other creditors (152,023 ) (22,249 )
Cash generated from operations 1,916,324 647,806

2. CASH AND CASH EQUIVALENTS

The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts:

Year ended 31 December 2024
31/12/24 1/1/24
£    £   
Cash and cash equivalents 87,934 20,986
Bank overdrafts (71,082 ) (67,580 )
16,852 (46,594 )
Year ended 31 December 2023
31/12/23 1/1/23
£    £   
Cash and cash equivalents 20,986 2,001
Bank overdrafts (67,580 ) (131,414 )
(46,594 ) (129,413 )


3. ANALYSIS OF CHANGES IN NET DEBT

At 1/1/24 Cash flow At 31/12/24
£    £    £   
Net cash
Cash at bank and in hand 20,986 66,948 87,934
Bank overdrafts (67,580 ) (3,502 ) (71,082 )
(46,594 ) 63,446 16,852
Debt
Debts falling due within 1 year (429,996 ) - (429,996 )
Debts falling due after 1 year (4,536,847 ) 427,283 (4,109,564 )
(4,966,843 ) 427,283 (4,539,560 )
Total (5,013,437 ) 490,729 (4,522,708 )

Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Notes to the Consolidated Financial Statements
for the Year Ended 31 December 2024

1. STATUTORY INFORMATION

Lindisfarne Healthcare(Holdings) Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the General Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

The financial statements are presented in pounds sterling.

Basis of consolidation
The group financial statements consolidate the financial statements of the company and it's subsidiary undertakings as at 31 December 2024. Uniform accounting policies are in place across the group and intercompany transactions and balances are eliminated on consolidation

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Transactions between group entities which have been eliminated on consolidation are not disclosed within the financial statements.

Turnover
Turnover represents the invoiced value of services provided to care users. The activities of the group are exempt from value added tax. Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company and that the revenue can be reliable measured.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2013, is being amortised evenly over its estimated useful life of ten years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.
Long leasehold - in accordance with the property
Plant and machinery - 2% on cost
Fixtures and fittings - at varying rates on cost

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.


Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

2. ACCOUNTING POLICIES - continued
Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Consolidated Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The group operates a defined contribution pension scheme. Contributions payable to the group's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS
2024 2023
£    £   
Wages and salaries 4,128,808 4,008,229
Other pension costs 69,624 142,345
4,198,432 4,150,574

The average number of employees during the year was as follows:
2024 2023

Directors 2 2
Management, Financial and Administrative 7 6
Nursing & Carers 109 118
Kitchen & Domestics 24 19
Maintenance & Activities 6 6
148 151

Wage & Salary costs for the year ended 31 December 2024 includes £339,581 (2023 £272,794) in respect of Social Security costs represented by Employers National Insurance Contributions.

During the year £69,624 has been charged to the income statement in respect of contributions made by the group to employers pensions

Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

3. EMPLOYEES AND DIRECTORS - continued

2024 2023
£    £   
Directors' remuneration 416,770 383,291

Information regarding the highest paid director is as follows:
2024 2023
£    £   
Emoluments etc 212,593 194,985

4. OPERATING PROFIT

The operating profit is stated after charging:

2024 2023
£    £   
Other operating leases 52,108 35,542
Depreciation - owned assets 96,480 96,480
Goodwill amortisation - 33,000
Auditors' remuneration 5,000 5,000

5. INTEREST PAYABLE AND SIMILAR EXPENSES
2024 2023
£    £   
Bank interest 20,440 15,846
Interest payable 345,652 327,935
366,092 343,781

6. TAXATION

Analysis of the tax charge
The tax charge on the profit for the year was as follows:
2024 2023
£    £   
Current tax:
UK corporation tax 126,462 82,071

Deferred tax 724,038 56,519
Tax on profit 850,500 138,590

Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

6. TAXATION - continued

Reconciliation of total tax charge included in profit and loss
The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The difference is explained below:

2024 2023
£    £   
Profit before tax 3,345,218 217,537
Profit multiplied by the standard rate of corporation tax in the UK of
25 % (2023 - 25 %)

836,305

54,384

Effects of:
Expenses not deductible for tax purposes 7,175 32,385
Depreciation in excess of capital allowances 7,020 51,821

Total tax charge 850,500 138,590

7. INDIVIDUAL INCOME STATEMENT

As permitted by Section 408 of the Companies Act 2006, the Income Statement of the parent company is not presented as part of these financial statements.


8. DIVIDENDS
2024 2023
£    £   
Ordinary shares of £1 each
Final 900,000 -

9. INTANGIBLE FIXED ASSETS

Group
Goodwill
£   
COST
At 1 January 2024
and 31 December 2024 330,000
AMORTISATION
At 1 January 2024
and 31 December 2024 330,000
NET BOOK VALUE
At 31 December 2024 -
At 31 December 2023 -

Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

10. TANGIBLE FIXED ASSETS

Group
Fixtures
Long Plant and and
leasehold machinery fittings Totals
£    £    £    £   
COST OR VALUATION
At 1 January 2024 4,189,018 947,489 1,575,063 6,711,570
Additions - 55,194 12,182 67,376
Revaluations 2,868,073 - - 2,868,073
At 31 December 2024 7,057,091 1,002,683 1,587,245 9,647,019
DEPRECIATION
At 1 January 2024 593,548 263,202 593,789 1,450,539
Charge for year 38,448 16,872 41,160 96,480
At 31 December 2024 631,996 280,074 634,949 1,547,019
NET BOOK VALUE
At 31 December 2024 6,425,095 722,609 952,296 8,100,000
At 31 December 2023 3,595,470 684,287 981,274 5,261,031

Long leasehold property incudes an interest in land based upon a lease of 125 years at a peppercorn rent from January 2007.

The business was revalued for loan security purposes in November 2024 by Cushman & Wakefield, Chartered Valuation Surveyors, in accordance with the RICS Valuation - Professional Standards January 2014 (Red Book) guidelines. They were of the opinion that the market value of the long leasehold interest in the care home on the assumption it is a fully operational and equipped entity and having regard to trading potential, free from encumbrance and as described in their report can be fairly stated at £12,500,000.

The directors have taken account of that information and assessed that the amount at which the leasehold interest is stated in the accounts should be restated to fair value and an adjustment has been made to reflect that together with provision for the deferred taxation arising.

Cost or valuation at 31 December 2024 is represented by:

Fixtures
Long Plant and and
leasehold machinery fittings Totals
£    £    £    £   
Valuation in 2024 2,868,073 - - 2,868,073
Cost 4,189,018 1,002,683 1,587,245 6,778,946
7,057,091 1,002,683 1,587,245 9,647,019

Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

11. FIXED ASSET INVESTMENTS

Group
Shares in
group
undertakings
£   
COST
At 1 January 2024
and 31 December 2024 3,667,923
NET BOOK VALUE
At 31 December 2024 3,667,923
At 31 December 2023 3,667,923
Company
Shares in
group
undertakings
£   
COST
At 1 January 2024
and 31 December 2024 3,124,539
NET BOOK VALUE
At 31 December 2024 3,124,539
At 31 December 2023 3,124,539

The group or the company's investments at the Balance Sheet date in the share capital of companies include the following:

Subsidiaries

Amos Nursing Homes Limited
Registered office: United Kingdom
Nature of business: Operation of a care home
%
Class of shares: holding
Ordinary 100.00
2024 2023
£    £   
Aggregate capital and reserves 3,254,673 1,659,957
Profit for the year 2,494,716 78,948

The shares in Amos Nursing Homes Limited are owned 100% by Lindisfarne Healthcare Limited which is not required to prepare consolidated accounts as it is a 100% subsidiary itself of Lindisfarne Healthcare (Holdings) Limited whose accounts consolidate the results of it's subsidiary and sub-subsidiary.

Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

11. FIXED ASSET INVESTMENTS - continued

Lindisfarne Healthcare Limited
Registered office: United Kingdom
Nature of business: Intermediate Holding Company
%
Class of shares: holding
Ordinary 100.00
2024 2023
£    £   
Aggregate capital and reserves 1,973,540 1,973,540


12. STOCKS

Group
2024 2023
£    £   
Stocks 35,000 35,000

13. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Group
2024 2023
£    £   
Trade debtors 241,203 365,518
Other debtors 211,113 1,198,428
Due from related company 418,687 418,687
Tax 296,258 296,258
Prepayments and accrued income 11,371 28,371
1,178,632 2,307,262

14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Group Company
2024 2023 2024 2023
£    £    £    £   
Bank loans and overdrafts (see note 16) 501,078 497,576 - -
Trade creditors 91,842 89,957 - -
Amounts owed to group undertakings - - 124,539 124,539
Tax 209,472 175,137 - -
Social security and other taxes 101,555 293,713 - -
Accruals and deferred income 155,684 117,434 - -
1,059,631 1,173,817 124,539 124,539

15. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR

Group
2024 2023
£    £   
Bank loans (see note 16) 4,109,564 4,536,847

Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

16. LOANS

An analysis of the maturity of loans is given below:

Group
2024 2023
£    £   
Amounts falling due within one year or on demand:
Bank overdrafts 71,082 67,580
Bank loans 429,996 429,996
501,078 497,576
Amounts falling due between two and five years:
Bank loans - 2-5 years 1,574,010 1,574,010
Amounts falling due in more than five years:
Repayable by instalments
Bank loans more 5 yr by instal 2,535,554 2,962,837

17. SECURED DEBTS

The following secured debts are included within creditors:

Group
2024 2023
£    £   
Bank loans 4,539,560 4,966,843

Bank and other loans are secured by a formal debenture over the assets of the companies in the group and by a fixed legal charge over the long leasehold property included in the accounts of a subsidiary company as described in these accounts. Cross guarantees also exist between the group companies in accordance with normal practice.

18. PROVISIONS FOR LIABILITIES

Group
2024 2023
£    £   
Deferred tax 1,127,695 403,657

Group
Deferred
tax
£   
Balance at 1 January 2024 403,657
Provided during year 724,038
Accelerated capital allowance
Balance at 31 December 2024 1,127,695

Lindisfarne Healthcare(Holdings) Limited (Registered number: 08751823)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

19. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
2 Ordinary £1 2 2

20. RESERVES

Group
Fair
Retained Share value
earnings premium reserve Totals
£    £    £    £   

At 1 January 2024 3,627,881 1,549,998 - 5,177,879
Profit for the year 2,494,718 2,494,718
Dividends (900,000 ) (900,000 )
Consolidation adjustments (2,151,055 ) - 2,151,055 -
At 31 December 2024 3,071,544 1,549,998 2,151,055 6,772,597


21. RELATED PARTY DISCLOSURES

As at 31 December 2024 an amount of £228,648 ( 31 December 2023 £1,128,648) is due from current or former directors. Other debtors also includes £418,687 (2023 :£504,325) due from a company under common control.

These loans are unsecured,repayable on demand and have no fixed interest terms

22. ULTIMATE CONTROLLING PARTY

The ultimate controlling parties of the company are the directors acting jointly in their capacity of executors of the estate of the late Mrs A F Kelly.